SCHEMBL3018152

SCHEMBL3018152

Cc1cccc(C)c1-c1csc(N2CCC(S(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
SMN1; SMN2 Q16637 6/20 0.40
MAPT P10636 2/20 0.40
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LIPE Q05469 1/20 0.39
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016159 0.92 FFAR4 (0.41) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3013083 0.90 AR (0.40) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3008527 0.90 SMN1; SMN2 (0.42) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3009914 0.89 SMN1; SMN2 (0.52) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3020525 0.86 RAB9A (0.49) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3007141 0.86 SMN1; SMN2 (0.49) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3012023 0.86 SMN1; SMN2 (0.50) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL3015106 0.86 SMN1; SMN2 (0.52) RAB9ANPC1SMN1; SMN2MAPTLIPE
SCHEMBL3014219 0.86 MAPT (0.49) RAB9ANPC1SMN1; SMN2MAPTUSP2
SCHEMBL3014068 0.85 RAB9A (0.44) RAB9ANPC1SMN1; SMN2MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.